Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Beware of Deep Water After Subthalamic Deep Brain Stimulation
Neurol 94:39-41, Waldvogel, D.,et al, 2020
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Candida Infections of the Central Nervous System
UptoDate Jan, Kauffman, C.A., 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Eur J Cancer 54:139-148, Michot, JM,.,et al, 2016
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Cryptococcal Meningoencephalitis in a Patient with Multiple Sclerosis Treated with Fingolimod
JAMA Neurol 72:1203-1205, Zhan, Y.,et al, 2015
Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014
Opportunistic Infections of the Retina in Patients with Aquaporin-4 Antibody Disease
JAMA Neurol 71:1429-1432, George, J.S.,et al, 2014
Retrospective Review of Cerebral Mycotic Aneurysms in 26 Patients: Focus on Treatment in Strongly Immunocompromised Patients with a Brief Literature Review
AJNR 34:823-827, Allen, L.M.,et al, 2013
Human Herpes 6 Virus Encephalitis Complicating Allogeneic Hematopoietic Stem Cell Transplantation
Neurol 80:1494-1500, Bhanushali, M.,et al, 2013
Aspergillus Meningitis: A Rare Clinical Manifestation of Central Nervous System Aspergillosis
J Infect 66:218-238, Antinori, S.,et al, 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Primary Varicella Zoster Infection Associated With Fingolimod Treatment
Neurol 76:1023-1024, Uccelli,A.,et al, 2011
Headache in Transplant Patients
www.medlink.com, Aug, Lai, T.H., 2011
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Neurologic Immune Reconstitution Inflammatory Syndrome in HIV/AIDS: Outcome and Epidemiology
Neurol 72:835-841, McCombe,J.A.,et al, 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Overweight After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Long Term Follow-Up
JNNP 80:484-488, Bannier,S.,et al, 2009
Psychogenic Tremor Occurring After Deep Brain Stimulation Surgery for Essential Tremor
Neurol 70:1498-1499, McKeon,A.,et al, 2008
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Pathological Gambling after Bilateral Subthalamic Nucleus Stimulation in Parkinson Disease
JNNP 78:517-519, Smeding,H.M.M.,et al, 2007
Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007
Suicide After Deep Brain Stimulation of the Internal Globus Pallidus for Dystonia
Neurol 66:142-143, Foncke,E.M.J.,et al, 2006
Panic and Fear Induced by Deep Brain Stimulation
JNNP 77:410-412, Shapira,HN.A.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
NEJM 354:980-982, Ozcan,C.,et al, 2006
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006
Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006
Pallidal Deep-Brain Stimulation in Primary Generalized or Segmental Dystonia
NEJM 355:1978-1990, Kupsch,A.,et al, 2006